SELLAS Life Sciences (SLS) Prepaid Assets (2010 - 2026)
SELLAS Life Sciences (SLS) reported Prepaid Assets of $4.0 million for Q1 2026, up 14.27% year-over-year from $3.5 million in Q1 2025, and up 19.71% on a QoQ basis from $3.3 million in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Prepaid Assets data on file, last reported at $4.0 million in Q1 2026.
- Quarterly Prepaid Assets rose 14.27% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 14.27% YoY) and the FY2025 annual result came in at $3.3 million, up 41.73% from the prior year.
- Prepaid Assets advanced to $4.0 million in Q1 2026 per SLS's latest filing, from $3.3 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $4.6 million in Q3 2025 and bottomed at $531000.0 in Q4 2022.
- The 5-year median for Prepaid Assets is $2.5 million (2022), against an average of $2.5 million.
- The widest annual swing landed in 2022, when Prepaid Assets plunged 66.58%; it then surged 331.92% in 2024.
- Tracing SLS's Prepaid Assets over 5 years: stood at $531000.0 in 2022, then grew by 2.07% to $542000.0 in 2023, then surged by 331.92% to $2.3 million in 2024, then soared by 41.73% to $3.3 million in 2025, then increased by 19.71% to $4.0 million in 2026.
- Per Business Quant, the three latest SLS Prepaid Assets figures stand at $4.0 million (Q1 2026), $3.3 million (Q4 2025), and $4.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.97 Mn |
| Dec 31, 2025 | 3.32 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 3.48 Mn |
| Dec 31, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 3.06 Mn |
| Mar 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | 542,000.00 |
| Sep 30, 2023 | 1.13 Mn |
| Jun 30, 2023 | 1.67 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Dec 31, 2022 | 531,000.00 |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 1.65 Mn |
| Mar 31, 2022 | 2.49 Mn |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 2.59 Mn |
| Jun 30, 2021 | 2.32 Mn |
| Mar 31, 2021 | 3.02 Mn |
| Dec 31, 2020 | 395,000.00 |
| Sep 30, 2020 | 1.03 Mn |
| Jun 30, 2020 | 1.79 Mn |
| Mar 31, 2020 | 1.94 Mn |
| Dec 31, 2019 | 557,000.00 |
| Sep 30, 2019 | 977,000.00 |
| Jun 30, 2019 | 776,000.00 |
| Mar 31, 2019 | 726,000.00 |
| Dec 31, 2018 | 387,000.00 |
| Sep 30, 2018 | 651,000.00 |
| Jun 30, 2018 | 931,000.00 |
| Mar 31, 2018 | 986,000.00 |
| Dec 31, 2017 | 337,000.00 |
| Sep 30, 2017 | 520,000.00 |
| Jun 30, 2017 | 434,000.00 |
| Mar 31, 2017 | 449,000.00 |
| Dec 31, 2016 | 332,000.00 |
| Sep 30, 2016 | 1.04 Mn |
| Jun 30, 2016 | 1.21 Mn |
| Mar 31, 2016 | 1.05 Mn |
| Dec 31, 2015 | 1.40 Mn |
| Sep 30, 2015 | 1.17 Mn |
| Jun 30, 2015 | 2.40 Mn |
| Mar 31, 2015 | 2.56 Mn |
| Dec 31, 2014 | 1.24 Mn |
| Sep 30, 2014 | 1.79 Mn |
| Jun 30, 2014 | 1.74 Mn |
| Mar 31, 2014 | 1.33 Mn |
| Dec 31, 2013 | 1.40 Mn |
| Sep 30, 2013 | 485,000.00 |
| Jun 30, 2013 | 389,000.00 |
| Mar 31, 2013 | 210,000.00 |
| Dec 31, 2012 | 535,000.00 |
| Sep 30, 2012 | 801,000.00 |
| Mar 31, 2012 | 290,000.00 |
| Dec 31, 2011 | 276,000.00 |
| Sep 30, 2011 | 494,000.00 |
| Jun 30, 2011 | 259,000.00 |
| Dec 31, 2010 | 150,000.00 |